 |
Featured Review
Cellscience Reviews Vol.2 No.4
ISSN 1742-8130 |
|
Novel Role for Cyclooxygenase Inhibitors in the Treatment of
N141I Presenilin 2 (PSEN-2) Familial Alzheimer’s Disease?
Weiping Qin 1, Breton S. Stetka 1 & Giulio Maria Pasinetti 1, 2, 3
1 Neuroinflammation Research Laboratories, Department of Psychiatry,
2 Department of Neuroscience, Department of Geriatrics
and Adult Development, and GRECC,
3 Bronx Veteran Affairs Medical Center, Mount Sinai School of Medicine, NY.
Abstract
Epidemiological studies have suggested that chronic administration of non-steroidal anti-inflammatory agents (NSAIDs), primarily cyclooxygenase (COX) inhibitors, may have a preventative effect in Alzheimer’s disease (AD). Despite this evidence, many recent trials have failed to demonstrate any therapeutic benefit of anti-inflammatory therapy in AD. The majority of NSAID trials in AD have been conducted in late disease stages at which point subjects may be refractory to any protective effect. On the other hand, as discussed in this review, recent studies provide support for the potential pharmacogenomic identification of N141I presenilin-2 (PSEN-2) familial Alzheimer’s disease (FAD)-cases that might be most likely to benefit from inhibition of the inducible form of COX, COX-2 during the progression of clinical FAD. We posit that further investigation must be conducted exploring NSAID therapy in those at risk for developing AD in particular N141I PSEN-2 FAD.
Please click 
to access complete issue ($4.95) and to download full article in 
or
formats 